Srinivas 'Srini' Shankar | Source | Global Head, Life Sciences, Chief Commercial Officer, Americas at Cognizant
Srinivas 'Srini' Shankar
Srini is an experienced client services executive with more than 25 years in Technology/Consulting/BPO across geographies and industry verticals with more than 15 years in Life Sciences. He has experience in P&L management with client accounts at differing levels of relationship maturity. He has successfully nurtured and sustained CXO, VP, Director level relationships with business and IT leaders in the industry. He has driven thought leadership & transformational business solutions.
-
Cognizant (https://www.cognizant.com/)
Global Head, Life Sciences, Chief Commercial Officer, Americas
-
Cognizant Discusses Generative AI’s Role in New Drug Development
Zohaib Sheikh: Hi, I'm Zohaib Sheikh, head of content at Fierce Life Sciences, and today I'm excited to speak with Srini Shankar, Chief Commercial Officer, Americas and Global Head, Life Sciences at Cognizant. Welcome, Srini.
Article
-
Generative AI has really taken off with the advent of ChatGPT, I think, which all of us know. So there's nothing new about that. I'm going to basically characterize AI before generative AI as quote unquote "conventional AI." So let's talk about conventional AI versus generative AI. If you think about conventional AI, which has been around for a while, but it has become more powerful with the advent of computing infrastructure and the evolution of computing infrastructure.
